Abstract: The invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of this form for medical purposes, methods for producing the crystalline form according to the invention, as well as pharmaceutical preparations comprising said form.

Abstract: The invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of this form for medical purposes, methods for producing the crystalline form according to the invention, as well as pharmaceutical preparations comprising said form.

Abstract: The present invention relates to a method for diagnosing a G-protein coupled receptor-related disease in one or more target cells, comprising: selecting a G-protein coupled receptor, the receptor being characterized in that it is: (i) differentially expressed in the target cells as compared to healthy control cells, wherein the expression level in the target cells is at least 10 times the expression level in the control cells; (ii) activated by a peptide ligand or a protein ligand; and (iii) upon activation by binding of a ligand efficiently internalized into the one or more target cells together the peptide ligand or protein ligand, wherein an internalization of at least 30% of the G-protein coupled receptor initially present in the cell membrane of the one or more target cells within less than 30 minutes after activation is indicative for the diagnosis of a G-protein coupled receptor-related disease.